Please login to the form below

Not currently logged in
Email:
Password:

Spain to delay €5.4bn in unpaid drug bills

Farmaindustria, the trade body for Spain's pharmaceutical industry, is in talks with Spanish authorities to defer payment of €5.4bn owed to its members

Farmaindustria, the trade body for Spain's pharmaceutical industry, is in talks with Spanish authorities to defer payment of €5.4bn owed to its members by the country's regional governments.

According to a report in Bloomberg, Humberto Arnes, director general of Farmaindustria, said the group is negotiating on a plan to sell state-guaranteed securities backed by the unpaid bills, with proceeds going towards pharmaceutical companies.

He said: "The mechanism allows a delay until Spain is in a financial and economic situation that allows it to face the pharmaceutical bill."

Work on the proposal was at a very advanced stage, according to Arnes, with plans to have a system in place that could defer payment for four to six years and include future unpaid bills.

Spain's current drugs debt stands at €5.4bn, up from €5.19bn in March, 2011, with payment of bills delayed an average of 430 days.

In August, 2011, Spain passed a law enforcing the prescribing and dispensing of generic drugs rather than the more expensive brands, in an attempt to save €2.4bn a year and reduce the country's deficit.

Find out more about the pharmaceutical industry in Spain in PMGroup's Focus on Spain.

5th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics